{"SPADE_UN_13426": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_13426", "Peptide Name": "Cbf-K-16 (variant of BF-30)", "Source": "Synthetic construct (Cbf-K16 is a variant of BF-30, which was found in the venom of the snake bungarus fasciatus)", "Family": "Not found", "Gene": "N/A", "Sequence": "KFFRKLKKSVKKRAKKFFKKPRVIGVSIPF", "Sequence Length": 30, "UniProt Entry": "No entry found", "Protein Existence": "Synthetic form", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-"], "Target Organism": "[Ref.31704464] Gram-negative drug-resistant clinical isolates:H. pylori SS1 (MIC = 16 μg/mL, MBC = 32 μg/mL); Gram -negative bacteria:H. pylori 26695 (MIC = 32 μg/mL, MBC = 64 μg/mL), H. pylori 11637 (MIC = 16 μg/mL, MBC = 64 μg/mL)[Ref.27287456] Gram-positive drug-resistant clinical isolates:MRSA strain no.1 (MIC = 32 μg/mL), MRSA strain no.2 (MIC = 16 μg/mL), S.aureus strain no.1 (MIC = 16 μg/mL), S.aureus strain no.2 (MIC = 64 μg/mL), S.aureus strain no.3 (MIC = 8 μg/mL), S.aureus strain no.4 (MIC = 16 μg/mL), S.aureus strain no.5 (MIC = 4 μg/mL), S.aureus strain no.6 (MIC = 8 μg/mL), S.aureus strain no.7 (MIC = 32 μg/mL), S.epidermidis strain no.1 (MIC = 16 μg/mL), S.epidermidis strain no.2 (MIC = 32 μg/mL);Gram-positive bacteria:S.aureus ATCC 25923 (MIC = 8 μg/mL);Gram-negative drug-resistant clinical isolates:E.coli strain no.1 (MIC = 4 μg/mL), E.coli strain no.2 (MIC = 8 μg/mL), E.coli strain no.3 (MIC = 8 μg/mL);Gram-negative bacteria:E.coli ATCC 25922 (MIC = 4 μg/mL)", "Hemolytic Activity": "[Ref.27287456]Cbf-K-16 has low hemolytic activity", "Cytotoxicity": "[Ref.27287456] Cbf-K-16 has low cytotoxicity.", "Binding Target": "Genomic DNA", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C177H295N49O33", "Mass": 3637.54, "PI": 12.0, "Net Charge": 13, "Hydrophobicity": -0.55, "Half Life": "Mammalian:1.3 hourYeast:3 minE.coli:2 min", "Comments": "Cbf-K16 possessed effective antimicrobial and anti-inflammatory activities and downregulated the expression of adhesion- and cytotoxin-associated genes of drug-resistant H. pylori SS1, making it a potential candidate for anti-infective therapy.", "Literature": [{"Title": "Antimicrobial activities of peptide Cbf-K 16 against drug-resistant Helicobacter pylori infection in vitro and in vivo.", "Pubmed ID": "31704464", "Reference": "Microb Pathog. 2020 Jan;138103847. doi 10.1016/j.micpath.2019.103847. Epub 2019 Nov 5.", "Author": "Jiang M, Ma L, Huang Y, Wu H, Dou J, Zhou C", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=31704464"}, {"Title": "The antimicrobial activity of Cbf-K16 against MRSA was enhanced by β-lactamantibiotics through cell wall non-integrity.", "Pubmed ID": "27287456", "Reference": "Arch Pharm Res. 2016 Jul;39(7)978-88. doi 10.1007/s12272-016-0769-x. Epub 2016 Jun 10.", "Author": "Bo Li, Wei Kang, Hanhan Liu, Yanrong Wang, Changzhong Yu, Xinyi Zhu, Jie Dou, Haibo Cai, Changlin Zhou", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=27287456"}, {"Title": "Effective antimicrobial activity of Cbf-K16 and Cbf-A7 A13 against nDM-1-carrying Escherichia coli by DnA binding after penetrating the cytoplasmic membrane in vitro", "Pubmed ID": "", "Author": "Hao Q, Wang H, Wang J, Dou J, Zhang M, Zhou W, Zhou C"}], "Frequent Amino Acids": "KFR", "Absent Amino Acids": "CDEHMNOQTUWY", "Basic Residues": 13, "Acidic Residues": 0, "Hydrophobic Residues": 14, "Polar Residues": 19, "Positive Residues": 13, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_06241", "Similarity": 1.0, "Sequence": "KFFRKKSVKK"}, {"SPADE_ID": "SPADE_N_06372", "Similarity": 1.0, "Sequence": "VKRFKKFFRKLKKSV"}, {"SPADE_ID": "SPADE_N_09466", "Similarity": 1.0, "Sequence": "VKRFKKFFRKLKKSVK"}]}}}